Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BEAMthis companyBeam Therapeutics Inc.	$27.00	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
ALLOAllogene Therapeutics, Inc.	$1.05	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
CRBUCaribou Biosciences, Inc.	$0.46	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
DTILPrecision BioSciences, Inc.	$10.38	-1.17×	0.58×	1.56×	0.68×	-257.3%	100.0%	-152.2%	-133.4%	-49.6%	-35.5%	-123.6%	0.31×	1.93×	-36.67×	13.32×	0.0%	3	-4.84	1	C-
EDITEditas Medicine, Inc.	$2.68	-1.14×	6.67×	4.49×	-0.75×	-308.6%	100.0%	-245.2%	-395.0%	-586.6%	-65.6%	-91.2%	2.81×	0.47×	-16.1×	3.54×	0.0%	3	-8.13	2	C
FATEFate Therapeutics, Inc.	$1.95	-0.85×	0.56×	17.56×	-1.16×	-121.9%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	3	-8.27	1	C-
Peer median	—	-1.14×	1.03×	4.49×	-1.13×	-257.3%	67.3%	-245.2%	-395.0%	-65.8%	-52.8%	-91.2%	0.31×	-0.1×	-16.1×	5.79×	0.0%	3	-7.25	2	—